Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,072,144
  • Shares Outstanding, K 537,533
  • Annual Sales, $ 28,190 M
  • Annual Income, $ 6,717 M
  • EBIT $ 6,218 M
  • EBITDA $ 10,289 M
  • 60-Month Beta 0.60
  • Price/Sales 5.75
  • Price/Cash Flow 11.34
  • Price/Book 21.34

Options Overview Details

View History
  • Implied Volatility 51.30% ( +4.67%)
  • Historical Volatility 25.95%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 51.30% on 11/14/24
  • IV Low 18.08% on 11/30/23
  • Put/Call Vol Ratio 0.72
  • Today's Volume 24,923
  • Volume Avg (30-Day) 11,718
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 214,965
  • Open Int (30-Day) 181,075

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.02
  • Number of Estimates 12
  • High Estimate 5.40
  • Low Estimate 4.71
  • Prior Year 4.71
  • Growth Rate Est. (year over year) +6.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
292.33 +1.23%
on 11/14/24
328.25 -9.85%
on 11/08/24
-28.69 (-8.84%)
since 10/14/24
3-Month
292.33 +1.23%
on 11/14/24
339.17 -12.75%
on 09/23/24
-26.80 (-8.30%)
since 08/14/24
52-Week
260.52 +13.59%
on 11/21/23
346.85 -14.68%
on 07/25/24
+25.91 (+9.60%)
since 11/14/23

Most Recent Stories

More News
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever

This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends.

BLK : 1,047.08 (+1.56%)
NVDA : 146.76 (+0.33%)
CSCO : 57.92 (-2.13%)
VZ : 40.87 (-0.66%)
CVX : 161.80 (+1.94%)
SCHD : 28.88 (-0.45%)
TXN : 206.00 (+0.14%)
AMGN : 295.93 (-1.83%)
BMY : 58.50 (+0.15%)
LMT : 538.99 (-3.36%)
UPS : 132.64 (-0.78%)
SCHW : 80.19 (+2.48%)
Trump Names Anti-Vaxxer Robert Kennedy As Health & Human Services Secretary: Here’s What It Means For Healthcare Stocks

Trump said his HHS Secretary nominee will ensure the public is protected from harmful substances that have aggravated the nation’s health crisis.

NVO : 105.32 (-1.49%)
IBB : 140.09 (-2.58%)
LLY : 786.23 (-3.15%)
MRNA : 39.77 (-5.62%)
AMGN : 295.93 (-1.83%)
XBI : 96.96 (-3.05%)
PFE : 26.02 (-2.62%)
BNTX : 103.56 (-7.10%)
SNY : 47.82 (-3.41%)
2 Dividend Stocks to Buy Hand Over Fist in November

These companies have solid businesses and excellent dividend growth track records.

ABBV : 169.63 (-0.42%)
AMGN : 295.93 (-1.83%)
Is Wall Street Bullish or Bearish on Amgen Stock?

Amgen has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

$SPX : 5,949.17 (-0.60%)
PJP : 85.81 (-1.91%)
AMGN : 295.93 (-1.83%)
PIPR : 331.39 (-0.86%)
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.01 per share. Core earnings of $2.08 per share fell 20% year over...

AZN : 65.04 (-0.38%)
AMGN : 295.93 (-1.83%)
SNY : 47.82 (-3.41%)
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?

Key TakeawaysLLY has declined 10.6% this month after disappointing third-quarter results.The drug maker has seen strong success in recent years, with several new drugs in the pipeline.Register now to see...

NVO : 105.32 (-1.49%)
LLY : 786.23 (-3.15%)
AMGN : 295.93 (-1.83%)
BIIB : 164.89 (-0.54%)
Investors Like Certainty. Trump's Win Gave Them Some.

We're also talking about Super Micro, Nvidia, and weight loss.

NVDA : 146.76 (+0.33%)
AAPL : 228.22 (+1.38%)
NVO : 105.32 (-1.49%)
SMCI : 18.01 (-11.41%)
HON : 230.67 (-1.03%)
BRK.AX : 0.500 (unch)
AMGN : 295.93 (-1.83%)
UNH : 593.15 (-2.10%)
COIN : 278.84 (-2.07%)
TSLA : 311.18 (-5.77%)
T : 22.25 (-0.22%)
INTC : 25.03 (+0.44%)
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus

Amgen AMGN reported third-quarter 2024 adjusted earnings of $5.58 per share, which beat the Zacks Consensus Estimate of $5.11. Earnings rose 13% year over year as higher revenues offset the impact of higher...

AZN : 65.04 (-0.38%)
NVO : 105.32 (-1.49%)
LLY : 786.23 (-3.15%)
AMGN : 295.93 (-1.83%)
Amgen (AMGN) Q3 2024 Earnings Call Transcript

AMGN earnings call for the period ending September 30, 2024.

AMGN : 295.93 (-1.83%)
Amgen: Q3 Earnings Snapshot

Amgen: Q3 Earnings Snapshot

AMGN : 295.93 (-1.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 304.99
2nd Resistance Point 301.73
1st Resistance Point 298.83
Last Price 295.93
1st Support Level 292.68
2nd Support Level 289.42
3rd Support Level 286.52

See More

52-Week High 346.85
Fibonacci 61.8% 313.87
Fibonacci 50% 303.68
Last Price 295.93
Fibonacci 38.2% 293.50
52-Week Low 260.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar